Bristol Myers Squibb recalls
Bristol Myers Squibb appears in 5 official U.S. recall notices indexed by RecallRadar, most recently on 2025-10-29.
Company names are normalized from agency data (legal suffixes removed), so related firms may appear under separate pages.
Recall summary
| Recall notices | 5 |
|---|---|
| Published | 2012-10-31 to 2025-10-29 |
| By agency | FDA Drug (5) |
| By classification | Class II (3), Class I (2) |
| By status | terminated (4), ongoing (1) |
| Distribution named in notices | US |
Recalls
- Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squib…
FDA Drug · Class II · 2025-10-29 · Bristol Myers Squibb
Reason: Lack of Assurance of Sterility. - EliquisTablets 5mg, 60 count bottle, Rx Only, Marketed by: Bristol-Meyers Squibb Company Princeton, NJ 08543 USA and Pfizer Inc
FDA Drug · Class I · 2017-07-19 · Bristol Myers Squibb
Reason: Labeling: Label Mix-up: One bottle of Eliquis 5 mg tablet was found to contain lower-strength Eliquis 2.5 mg tablets only instead of the labeled 5 mg tablets. - Kombiglyze XR (saxagliptin and metformin HCl extended-release) tablets, Physician Sample-Not For Sale, 6 Tablets per Carton, 2.5 mg/1000 mg…
FDA Drug · Class II · 2012-10-31 · Bristol Myers Squibb
Reason: Labeling; Correct labeled product miscart/mispack: Some Physician sample cartons were incorrectly labeled as Kombiglyze XR 2.5mg/1000mg on the external package carton, whereas the contents were Kombiglyze XR 5 mg/500 mg… - Kombiglyze XR (saxagliptin and metformin HCl extended-release) tablets, Physician Sample-Not For Sale, 7 Tablets per Carton, 5 mg/500 mg, R…
FDA Drug · Class II · 2012-10-31 · Bristol Myers Squibb
Reason: Labeling; Correct labeled product miscart/mispack: Some Physician sample cartons were incorrectly labeled as Kombiglyze XR 2.5mg/1000mg on the external package carton, whereas the contents were Kombiglyze XR 5 mg/500 mg… - BiCNU (Carmustine for injection) 100 mg and Diluent Rx Only BiCNU manufactured by: Ben Venue Laboratories, Inc
FDA Drug · Class I · 2012-10-31 · Bristol Myers Squibb
Reason: Superpotent (Single Ingredient) Drug: All BiCNU lots within expiration which contain carmustine vial lots manufactured by BenVenue Laboratories (BVL) are being recalled because of an overfilled vial discovered during st…